Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Blood Cancer J ; 12(1): 8, 2022 01 18.
Article in English | MEDLINE | ID: covidwho-1630561


Understanding antibody-based SARS-CoV-2 immunity in hematologic malignancy (HM) patients following infection is crucial to inform vaccination strategies for this highly vulnerable population. This cross-sectional study documents the anti-SARS-CoV-2 humoral response and serum neutralizing activity in 189 HM patients recovering from a PCR-confirmed infection. The overall seroconversion rate was 85.7%, with the lowest values in patients with lymphoid malignancies or undergoing chemotherapy. Therapy-naive patients in the "watch and wait" status were more likely to seroconvert and display increased anti-s IgG titers. Enhanced serum neutralizing activity was observed in the following SARS-CoV-2-infected HM patient groups: (i) males; (ii) severe COVID-19; and (iii) "watch and wait" or "complete/partial response". The geometric mean (GeoMean) ID50 neutralization titers in patients analyzed before or after 6 months post-infection were 299.1 and 306.3, respectively, indicating that >50% of the patients in either group had a neutralization titer sufficient to provide 50% protection from symptomatic COVID-19. Altogether, our findings suggest that therapy-naive HM patients mount a far more robust immune response to SARS-CoV-2 infection vs. patients receiving anti-cancer treatment, raising the important question as to whether HM patients should be vaccinated before therapy and/or receive vaccine formats capable of better recapitulating the natural infection.

Antibodies, Neutralizing/immunology , Antibodies, Viral/immunology , Antineoplastic Agents/administration & dosage , COVID-19/immunology , Hematologic Neoplasms , Immunity, Humoral , SARS-CoV-2/immunology , Aged , Female , Hematologic Neoplasms/drug therapy , Hematologic Neoplasms/immunology , Humans , Male , Middle Aged